Blackstone Inc
CBIO icon

Blackstone Inc’s Crescent Biopharma CBIO Stock Holding History

Blackstone Inc’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
+62,647
New +$1.22M ﹤0.01% 243
2026
Q1 		– Sell
-75,614
Closed -$897K – 452
2025
Q4 		$897K Hold
75,614
– – ﹤0.01% 226
2025
Q3 		$899K Hold
75,614
– – ﹤0.01% 209
2025
Q2 		$1.22M Buy
+75,614
New +$1.6M 0.01% 118
2015
Q1 		– Sell
-166
Closed -$119K – 61
2014
Q4 		$119K Buy
+166
New +$130K ﹤0.01% 53

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Blackstone Inc's CBIO Position: Q2 2026 in Review

Blackstone Inc opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 62,647 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #243 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in CBIO as recently as Q4 2025.

Blackstone Inc first reported a position in CBIO in Q4 2014 and has held it in 5 quarters since. The position peaked at $1.22M in Q2 2025. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Blackstone Inc held 62,647 shares of Crescent Biopharma worth $1.13M as of Q2 2026.
  • Crescent Biopharma was a new Blackstone Inc position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #243 holding.
  • Blackstone Inc first reported a position in Crescent Biopharma in Q4 2014 and has held it in 5 quarters since.
  • Blackstone Inc's Crescent Biopharma position peaked at $1.22M in Q2 2025.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.